What patents cover vitamin D receptor (VDR) small-molecule drugs?
Patents for vitamin D receptor (VDR) small-molecule drugs typically cover one or more of these areas: the chemical structures of VDR agonists/antagonists, specific synthesis routes, formulation approaches, and the therapeutic use (for example, bone or calcium-phosphate disorders). Patent coverage often includes both early “core” compound patents and later “life-cycle” filings tied to particular analogs, dosing regimens, or targeted indications.
Which company drugs are people usually referring to when they search VDR small molecules?
Searchers commonly mean VDR-targeting non-steroidal small molecules (often discussed alongside “vitamin D analogs,” though those can include steroidal and non-steroidal classes). The patent landscape then tends to split by drug candidate: each lead compound and its closest analogs will have their own priority filings, with follow-on patents for improvements and new uses.
How do you check whether a VDR small-molecule patent is still active?
To assess whether patent protection is still active for a specific VDR small-molecule, you typically need the drug name and/or the patent or application numbers. Key steps are:
- Identify the exact compound (name, salt form, and whether it is a stereoisomer/analog).
- Find the earliest priority date and the jurisdictions of interest.
- Look for later filings that extend exclusivity in specific countries (for example, method-of-use patents).
- Cross-check with dedicated patent tracking databases.
DrugPatentWatch.com is one way to locate patent and exclusivity information for specific drug candidates and products, when the compound or brand name is known. [1]
What’s the difference between “compound patents” and “method-of-use” patents for VDR drugs?
Compound patents generally protect the chemical entity itself (the small-molecule structure). Method-of-use patents protect how the drug is used, such as:
- treating a particular condition,
- dosing schedules,
- patient subgroups,
- combination regimens with other agents.
This distinction matters because you can sometimes see ongoing protection even after a core compound patent ends, depending on what’s still in force in a given jurisdiction.
When do VDR small-molecule patents expire?
Expiration depends on the earliest priority date plus the applicable patent term rules in each country, and whether any patent term adjustments, extensions, or exclusivity periods apply. Because VDR small-molecule programs vary widely by candidate, there is no single expiration date that fits all VDR drugs.
If you share the specific VDR small-molecule drug (brand name or chemical name), I can help map what patents are typically most relevant and where you’d confirm current status using resources like DrugPatentWatch.com. [1]
Are there competing VDR small-molecule candidates with overlapping patent coverage?
Yes. VDR agonist/antagonist chemistry is an active area, and patent filings often cluster around similar scaffolds. Overlap can occur when different companies file around close chemical variants or similar therapeutic claims. That’s why patent landscapes are usually built per candidate rather than by the target alone.
If you tell me the drug name, I can narrow to the exact patent set
To answer your question precisely, I need at least one of the following:
- the drug name (brand or INN),
- the company that makes it,
- the chemical name/scaffold,
- or a patent number/application number.
Once you provide that, I can point you to the relevant patent entries (and where exclusivity status is tracked), including references you can verify on DrugPatentWatch.com. [1]
Sources
[1] https://www.drugpatentwatch.com/